- Home
- BRIA vs IKNA Comparison
BRIA vs IKNA Comparison
Compare BRIA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- IKNA
- Stock Information
- Founded
- BRIA 2011
- IKNA 2016
- Country
- BRIA Singapore
- IKNA United States
- Employees
- BRIA N/A
- IKNA N/A
- Industry
- BRIA
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- IKNA Health Care
- Exchange
- BRIA NYSE
- IKNA Nasdaq
- Market Cap
- BRIA 73.0M
- IKNA 61.8M
- IPO Year
- BRIA 2024
- IKNA 2021
- Fundamental
- Price
- BRIA $2.09
- IKNA $1.25
- Analyst Decision
- BRIA
- IKNA Buy
- Analyst Count
- BRIA 0
- IKNA 2
- Target Price
- BRIA N/A
- IKNA $3.00
- AVG Volume (30 Days)
- BRIA 28.2K
- IKNA 79.8K
- Earning Date
- BRIA 05-15-2025
- IKNA 03-06-2025
- Dividend Yield
- BRIA N/A
- IKNA N/A
- EPS Growth
- BRIA N/A
- IKNA N/A
- EPS
- BRIA 92.24
- IKNA N/A
- Revenue
- BRIA $55,755,669.00
- IKNA N/A
- Revenue This Year
- BRIA N/A
- IKNA N/A
- Revenue Next Year
- BRIA N/A
- IKNA N/A
- P/E Ratio
- BRIA $0.02
- IKNA N/A
- Revenue Growth
- BRIA 8.03
- IKNA N/A
- 52 Week Low
- BRIA $1.85
- IKNA $1.19
- 52 Week High
- BRIA $4.38
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- IKNA 36.42
- Support Level
- BRIA N/A
- IKNA $1.27
- Resistance Level
- BRIA N/A
- IKNA $1.43
- Average True Range (ATR)
- BRIA 0.00
- IKNA 0.07
- MACD
- BRIA 0.00
- IKNA -0.00
- Stochastic Oscillator
- BRIA 0.00
- IKNA 25.00
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.